252 related articles for article (PubMed ID: 16827986)
1. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
[TBL] [Abstract][Full Text] [Related]
2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
4. [Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].
Gómez Camarero P; Martínez Brocca MA; Rodríguez Rodríguez JR; Navarro González E; Tirado Hospital JL; González Duarte D; Vázquez Albertino R; Astorga Jimenez R
Rev Esp Med Nucl; 2003; 22(5):295-305. PubMed ID: 14534005
[TBL] [Abstract][Full Text] [Related]
5. [Application of recombinant human TSH in the diagnostic protocol of differentiated thyroid carcinoma].
Jiménez-Hoyuela García JM; García Almeida JM; Delgado García A; Aguilar Fernández I; Martínez del Valle Torres MD; Ortega Lozano S; Rebollo Aguirre A; Mancha Doblas I; Pinzón Martín JL; Picón César MJ; Zamorano Vázquez D
Rev Esp Med Nucl; 2005; 24(3):152-60. PubMed ID: 15847782
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma].
Rajkovaca Z; Kovacević P; Stanetić M; Ristić S
Vojnosanit Pregl; 2012 Nov; 69(11):941-6. PubMed ID: 23311243
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
10. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
[TBL] [Abstract][Full Text] [Related]
12. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
Roelants V; Nayer PD; Bouckaert A; Beckers C
Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
[TBL] [Abstract][Full Text] [Related]
14. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
[TBL] [Abstract][Full Text] [Related]
15. Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection.
Verburg FA; de Keizer B; de Klerk JM; Lentjes EG; Lips CJ; van Isselt JW
Nuklearmedizin; 2009; 48(1):26-9. PubMed ID: 19212608
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
[TBL] [Abstract][Full Text] [Related]
18. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
20. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
